NL-OMON40257已完成3 期
Exploratory open label study to investigate the effect of teriflunomide on immune cell subsets in the blood of patients with relapsing forms of multiple sclerosis - TERI-DYNAMIC
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients (male and female) with relapsing forms of multiple sclerosis meeting McDonald criteria for MS at the screening visit and having either one of the following treatment status:
- •- Naïve to disease modifying (DM) treatment or no DM treatment for more than 2 years
- •- Or currently (not more than 3 months interruption) on MS therapy with IFN *-1 or Glatiramer acetate and a period of at least 2 weeks without IFN *-1 or Glatiramer acetate before switching to teriflunomide.
- •- Male and female patients, between 18 and 56 years of age, exclusive.;Healthy volunteers:
- •- Male and female subjects, between 18 and 56 years of age, exclusive.
- •- Body weight between 50.0 and 95.0 kg, inclusive, if male; and between 40.0 and 85.0 kg, inclusive, if female, body mass index between 18.0 and 30.0 kg/m2, inclusive.
- •- Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
- •- Normal vital signs after 10 minutes resting in supine position:
- •* 95 mmHg < systolic blood pressure (SBP) <140 mmHg
- •* 45 mmHg < diastolic blood pressure (DBP) <90 mmHg
- •* 40 bpm < heart rate (HR) <100 bpm
- •- Normal standard 12-lead electrocardiogram (ECG) after 10 minutes resting in supine position; 120 ms < PR <220 ms, QRS <120 ms, QTc * 430 ms if male, * 450 ms if female.
- •- Laboratory parameters within the normal range (or defined screening threshold for the Investigator site), unless the Investigator considers an abnormality to be clinically irrelevant for healthy subjects; however liver function parameter(s) should not exceed the upper laboratory norm.
排除标准
- •- Did not consent to HIV testing (the specifics of informed consent process for the HIV testing should be done in accordance with local guidelines).
- •- A relapse within 30 days prior to screening.
- •- Clinically relevant cardiovascular, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the patient at risk by participating in the study.
- •- Patients with a congenital or acquired severe immunodeficiency, a history of cancer (except for basal or squamous cell skin lesions which have been surgically excised, with no evidence of metastasis), lymphoproliferative disease, or any patient who has received lymphoid irradiation.
- •- Human immunodeficiency virus (HIV) positive patients.
- •- Known history of active tuberculosis not adequately treated or positive QuantiFERON TB Gold test.
- •- Hypoproteinemia (eg, in case of severe liver disease or nephrotic syndrome) with serum albumin <3.0 g/dL.
- •- Moderate to severe impairment of renal function, as shown by serum creatinine >133 *mol/L (or >1.5 mg/dL).
- •- Patients with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia.
- •- Acute or chronic infection.
- •- Liver function impairment or persisting elevations >1.5ULN (confirmed by retest) of serum glutamic pyruvic transaminase/ alanine aminotransferase (SGPT/ALT), serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST), or direct bilirubin greater than 1.5-fold the
- •upper limit of normal.
- •- Known history of hepatitis.
- •- Use of adrenocorticotrophic hormone (ACTH) or systemic corticosteroids for 2 weeks prior to screening.
- •- Prior or concomitant use of cytokine therapy or intravenous immunoglobulins in the 3 months prior to screening.
- •- Prior use of alemtuzumab or cladribine.
- •- Prior use (within 1 year) of fingolimod (Gylenia®).
- •- Prior use (within 2 years) of mitoxantrone, natalizumab (Tysabri®), or immunosuppressant agents (i.e. azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate).
- •- Prior treatment with teriflunomide, and prior or concomitant use of leflunomide (ARAVA®) or hypersensitivity to any of the other ingredients or excipients of the investigational product.
- •- Prior use of any investigational drug in the 6 months preceding screening.
- •- Pregnant or breast-feeding women.
- •- Women of childbearing potential not utilizing effective contraceptive method and /or women of childbearing potential who are unwilling to or unable to be tested for pregnancy.
- •- Known history of hypersensitivity to teriflunomide or leflunomide.
- •- Persisting elevations (confirmed by retest) of serum amylase or lipase greater than 2-fold the upper limit of normal.
- •- Known history of chronic pancreatic disease or pancreatitis.;Healthy volunteers:
- •- Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
- •- Blood donation, any volume, within 2 months before inclusion or according to local regulations).
- •- Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic b
研究者
相似试验
进行中（未招募）
不适用
Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosismultiple sclerosisEUCTR2012-005324-16-BEGenzyme Corporation68
进行中（未招募）
不适用
Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosismultiple sclerosisEUCTR2012-005324-16-NLGenzyme Corporation68
进行中（未招募）
不适用
Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple SclerosisMedDRA version: 14.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersmultiple sclerosisEUCTR2012-005324-16-DEGenzyme Corporation68
已完成
不适用
Study of dietary fiber supplement to improve triglycerides and plasma glucose levels in subjects with elevated LDL levels.CTRI/2012/12/003220Spectrum Clinical Research Pvt Ltd60
进行中（未招募）
1 期
The purpose of the research study is to determine if domatinostat in combination with avelumab will be able to delay or prevent worsening of the disease in patients with advanced unresectable/metastatic Merkel Cell Carcinoma that is continuing to grow after previous anti-PD-(L)1 antibody therapy. Furthermore, safety of the combination during the study conduct will be assessed.patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD(L)1 antibody therapyMedDRA version: 21.1Level: LLTClassification code 10064025Term: Merkel cell carcinomaSystem Organ Class: 100000004864EUCTR2018-004788-30-FR4SC AG40